Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox (Mpox) Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Outline
- What is the problem?
- Relationship to other symptoms
- Is impairment global or domain-specific?
- Who is affected?
- When do deficits arise?
- Consequences
- What underlies the problem? Aetiology
- Genetics (1)
- Genetics (2)
- Environment – ethnic minority status
- Environment – urban environments
- Environment – cannabis
- Environment – prenatal infection and obstetric complications
- Environment – vascular risk factors
- What is the problem? Pathophysiology
- Biological basis of cognitive impairment
- Cognitive impairment at the molecular level
- Evidence of cognitive impairment
- Dopamine (1)
- Dopamine (2)
- Dopamine (3)
- Acetylcholine (1)
- Acetylcholine (2)
- How can we fix the problem?
- Existing treatments
- Novel treatments: cannabidiol
- Novel treatments: muscarinic agonism (1)
- Novel treatments: muscarinic agonism (2)
- Novel treatments: glutamatergic modulation (1)
- Novel treatments: glutamatergic modulation (2)
- Outstanding questions
- Conclusion
- Acknowledgements
Topics Covered
- Psychosis
- Schizophrenia
- Aetiology of cognitive disorder
- Pathophysiology of cognitive disorder
- Biological basis of cognitive impairment
- Evidence of cognitive impairment
- Existing and novel treatments
Talk Citation
McCutcheon, R. (2024, June 30). Cognitive symptoms of psychosis: aetiology, neurobiology, & treatment [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 23, 2024, from https://doi.org/10.69645/FXQH1591.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Robert McCutcheon has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Neuroscience
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, My name is
Robert McCutcheon
and I'm a Psychiatrist
and a Researcher.
In both my clinical
and my academic work,
I'm really interested in
the cognitive
symptoms of psychosis
and that's what I'm going
to be talking about today.
0:22
I'm going to start by
really discussing
what the problem is.
Then I'm going to discuss
how this problem arises.
What are the causative factors
beneath cognitive
impairment in psychosis?
Then finally, I'm going to think
about how we go around
addressing this.
What are the potential
clinical interventions that
we can make to treat cognitive
symptoms in psychosis?
0:53
Why is it worth
thinking about this?
First of all, it's
highly prevalent.
The graph shows
a distribution of
cognitive scores.
You can see the control
population in blue
and the people with
schizophrenia in orange.
You can see that there's really
a quite profound shift
in the performance
on cognitive tests compared to
the control population.
Of course, if it was
highly prevalent but
of no consequence,
we wouldn't mind that much.
The reason we mind is because it
has a really major
impact on functioning.
Cognitive symptoms
are really one of
the main reasons why
people with psychosis
aren't able to reach
their full potential,
and contributes to
unemployment and
inability to live independently.
The other reason is because
we don't currently have
good treatments for this.
The standard dopamine-blocking
agents we use
are effective for
hallucinations and delusions
but really don't
have much benefit,
and can at times even be harmful
when it comes to
cognitive symptoms.
Hide